(Journal Article): Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
 
Meier JJ, Gallwitz B, Nauck MA
 
IN: BioDrugs 2003; 17(2):93-102
Impact Factor(s) of BioDrugs: 1.905 (2004), 2.277 (2003), 0.503 (2001)

ABSTRACT: Although the insulinotropic actions of gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been known for almost 2 decades, the incretin hormones have not... Click HERE for details